![](https://webarchive.library.unt.edu/web/20090114092716im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20090114092716im_/http://www.cancer.gov/images/spacer.gif)
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified
virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) Types 6, 11, 16, and 18 with immunoprophylactic activity. The immunoprohylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, appear to be mediated by the development of humoral immune
responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/web/20090114092716im_/http://www.cancer.gov/images/spacer.gif)
US brand name: | ![](https://webarchive.library.unt.edu/web/20090114092716im_/http://www.cancer.gov/images/spacer.gif) | Gardasil | | ![](https://webarchive.library.unt.edu/web/20090114092716im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20090114092716im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20090114092716im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20090114092716im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20090114092716im_/http://www.cancer.gov/images/spacer.gif) |